Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Other Accumulated Expenses (2023 - 2025)

Cytosorbents (CTSO) has disclosed Other Accumulated Expenses for 2 consecutive years, with $965000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Accumulated Expenses changed N/A year-over-year to $965000.0, compared with a TTM value of $965000.0 through Jun 2025, changed N/A, and an annual FY2024 reading of $812000.0, changed N/A over the prior year.
  • Other Accumulated Expenses was $965000.0 for Q2 2025 at Cytosorbents, up from $812000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $965000.0 in Q2 2025 and bottomed at $812000.0 in Q4 2024.